Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CLINUVEL files Canadian New Drug Submission For SCENESSE® in EPP
Details : Scenesse® (afamelanotide) activates human pigmentation, reduce oxidative damage, inflammation and swelling, and optimise the response of skin cells to UV-induced damage in EPP.
Brand Name : Scenesse
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 30, 2024
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clinuvel Trial Results Show Drug Reduces DNA Damage
Details : Scenesse® (afamelanotide) belongs to the family of melanocortins, hormones, which activates human pigmentation, reduce oxidative damage, inflammation and swelling, and optimise the response of skin cells to UV-induced damage. It is being investigated fo...
Brand Name : Scenesse
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Afamelanotide
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CLINUVEL Progresses Vitiligo Treatment Program
Details : CLINUVEL’s initial studies in vitiligo patients showed that Scenesse (afamelanotide) could repigment skin in combination with a light-based therapy, with nearly 100 patients receiving treatment to date and the safety profile of the drug maintained.
Brand Name : Scenesse
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 10, 2022
Lead Product(s) : Afamelanotide
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Afamelanotide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Stroke Patient Treated with Afamelanotide
Details : The CUV801 study is evaluating the use of afamelanotide in six patients who suffered an acute stroke, with a main focus on safety monitoring following drug administration as they are admitted to hospital.
Brand Name : Scenesse
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 07, 2021
Lead Product(s) : Afamelanotide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clinuvel Progresses Innovative DNA Repair Program
Details : Having commercialised SCENESSE® in Europe and the USA for the rare genetic disorder porphyria (EPP), CLINUVEL is expanding its clinical research, aiming to confirm how intervention with the drug enhances elimination of photoproducts and regeneration of ...
Brand Name : Scenesse
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 10, 2020
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?